Category: Abbott Laboratories
Abbott Diabetes Care issues a recall of its FreeStyle blood glucose test strips.
Abbott Diabetes Care (NYSE:ABT) said it issued a recall of its FreeStyle blood glucose test strips after reports of falsely low results.
A coalition of physicians' groups petition the Centers for Medicare & Medicaid to issue a coverage decision for transcatheter mitral valve implantation systems such as Abbott Labs' recently approved MitraClip.
Kardiametrics sues a raft of big-name medical device companies, including Boston Scientific, Abbott and Covidien, alleging infringement of its patents for blood clot protection devices.
Abbott says it's planning an immediate U.S. launch of its MitraClip heart device now that the FDA has granted pre-market approval for the mitral regurgitation treatment.
Abbott (NYSE:ABT) said it's planning an immediate launch in the U.S. for its MitraClip device now that the FDA has granted a long-awaited pre-market approval for the device, which is designed to treat mitral valve regurgitation.
Abbott's 3rd-quarter earnings beat Wall Street's expectations despite missing The Street's sales target, sending shares up more than 1% in pre-market trading.
Abbott (NYSE:ABT) shares ticked up today ahead of the market's open after the healthcare giant beat Wall Street's earnings expectations despite missing its 3rd-quarter sales target.
Abbott posted profits of $966 million, or 61¢ per share, on sales of $5.37 billion for the 3 months ended Sept. 30, for a 50.3% profit slide on sales growth of 2.0% compared with Q3 2012. Analysts had expected sales of $5.77 billion.
The U.S. Court of Appeals for the Federal Circuit declines to revisit its decision to uphold a lower court's decision to invalidate patents for drug-eluting coronary stent technology.
A federal appeals court last week declined to revisit its decision to uphold the invalidation of patents covering drug-eluting stent technology.
Ireland finance minister Michael Noonan rejects a report claiming that medical device giants Boston Scientific and Abbott Labs paid little to no taxes on billions in profits.
MASSDEVICE ON CALL — Irish finance minister Michael Noonan denied "emphatically" a recent report putting Boston Scientific's (NYSE:BSX) and Abbott's (NYSE:ABT) effective corporate tax rates in the country at 4% and 0%, respectively.